Last reviewed · How we verify
Weight Based Group
This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels.
This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors.
At a glance
| Generic name | Weight Based Group |
|---|---|
| Sponsor | University of Colorado, Denver |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, the drug decreases glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and reduced glucose levels in the blood. This results in improved glycemic control and weight loss in patients with type 2 diabetes.
Approved indications
- Treatment of type 2 diabetes
- Reduction of major adverse cardiovascular events in patients with established cardiovascular disease or multiple cardiovascular risk factors
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- "Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" (NA)
- Comparison of the Effects of Free Weight and Machine-Based Exercises on Muscular Parameters (NA)
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients (NA)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS) (PHASE3)
- Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention
- IASTM and Vibration Effects on Pain, Functionality, and Kinesiophobia in Lumbar Disc Herniation (NA)
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Weight Based Group CI brief — competitive landscape report
- Weight Based Group updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI